Non-inferiority study of telaprevir dose reduction regimen on telaprevir with pegylated interferon and ribavirin therapy for treatment-experienced patients with chronic hepatitis C genotype 1; prospective randomized controlled, multicenter trial.
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 Jul 2017 Status changed from recruiting to completed.
- 05 Nov 2013 Interim results (n=66) presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases.
- 21 Feb 2012 New trial record